1. Home
  2. AGIO vs NBHC Comparison

AGIO vs NBHC Comparison

Compare AGIO & NBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$37.22

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo National Bank Holdings Corporation

NBHC

National Bank Holdings Corporation

HOLD

Current Price

$37.99

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
NBHC
Founded
2007
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2013
2011

Fundamental Metrics

Financial Performance
Metric
AGIO
NBHC
Price
$37.22
$37.99
Analyst Decision
Buy
Buy
Analyst Count
10
4
Target Price
★ $46.00
$44.00
AVG Volume (30 Days)
★ 1.0M
430.4K
Earning Date
11-05-2026
10-27-2026
Dividend Yield
N/A
★ 3.37%
EPS Growth
N/A
★ N/A
EPS
N/A
★ 1.04
Revenue
$43,011,000.00
★ $47,100,000.00
Revenue This Year
$229.47
$25.73
Revenue Next Year
$94.99
$7.50
P/E Ratio
★ N/A
$36.57
Revenue Growth
N/A
★ 2.86
52 Week Low
$22.24
$35.06
52 Week High
$46.00
$47.28

Technical Indicators

Market Signals
Indicator
AGIO
NBHC
Relative Strength Index (RSI) 67.97 39.03
Support Level $32.17 $37.12
Resistance Level $44.09 $42.66
Average True Range (ATR) 1.34 0.67
MACD 0.66 0.10
Stochastic Oscillator 98.33 58.61

Price Performance

Historical Comparison
AGIO
NBHC

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About NBHC National Bank Holdings Corporation

National Bank Holdings Corp offers a full range of banking products and financial services to commercial, business, and consumer clients predominantly in Colorado, with a focus on personalized service through relationship managers and banking center associates. The company provides commercial and industrial loans, non-owner occupied commercial real estate loans, Small Business Administration loans as a Preferred Lender Provider, U.S. Department of Agriculture and Farm Service Agency loans, commercial deposit and treasury management products, business online and mobile banking, consumer and residential real estate loans, deposit services, and trust and wealth management services. Its services emphasize full-relationship banking, integrating lending, deposits, and cash management solutions.

Share on Social Networks: